Gobiquity, Inc
Form 483 issued February 12, 2026 · Nashville, Tennessee
- Inspection
- Feb 9 – Feb 12, 2026
- Investigator
- Jamie P. Webb
- Observations
- 2
- Pages
- 7
- FEI number
- 3010539401
In short: On February 12, 2026, FDA issued a Form 483 with 2 observations to Gobiquity, Inc in Nashville, Tennessee (FEI 3010539401) after an inspection that ran Feb 9 – Feb 12, 2026. The investigator was Jamie P. Webb. The most-cited regulation is 21 CFR 4.1 (what is the scope of this subpart?).
What FDA observed
Preview: the opening words of each observation- 01ISO 13485:2016 Clause 4.1.2
A risk-based approach to the control of the appropriate processes needed for the quality management system…
- 02ISO 13485:2016 Clause 7.3.9
Design and development changes were not adequately reviewed, verified, validated, and approved before implementation. Your firm…
This inspection in context
Questions about this 483
What did FDA find at Gobiquity, Inc?
FDA listed 2 observations on this Form 483. The most-cited regulation is 21 CFR 4.1 (what is the scope of this subpart?). The opening words of each observation are shown on this page.
Who inspected Gobiquity, Inc?
Jamie P. Webb is named on this Form 483, for the inspection of Feb 9 – Feb 12, 2026. Each investigator has a profile showing what they cite most.
When was Gobiquity, Inc inspected by FDA?
The inspection ran Feb 9 – Feb 12, 2026, and the Form 483 is dated February 12, 2026.
How do I get the full Form 483 for Gobiquity, Inc?
Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.